Unknown

Dataset Information

0

Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.


ABSTRACT: BACKGROUND:Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates. METHODS:The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with <8 weeks of antiretroviral treatment before delivery (NCT01511237). Infants received a 2-week course of zidovudine/lamivudine/NVP (NVP syrup/once daily: 2 mg/kg for 7 days; then 4 mg/kg for 7 days). Infant samples were assessed during the first 2 weeks of life. NVP population pharmacokinetics (PK) parameters were estimated using nonlinear mixed-effects models. Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis (>0.10 mg/L) and for therapeutic efficacy (>3.0 mg/L) using different infant dosing strategies. RESULTS:Sixty infants (55% male) were included. At birth, median (range) weight was 2.9 (2.3-3.6) kg. NVP concentrations were best described by a 1-compartment PK model. Infant weight and postnatal age influenced NVP PK parameters. Based on simulations for a 3-kg infant, ?92% would have an NVP trough >0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens. For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough >3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks. CONCLUSION:WHO weight-band prophylactic guidelines achieved target concentrations. Starting NVP 6 mg/kg twice daily from birth is expected to achieve therapeutic concentrations during the first 2 weeks of life.

SUBMITTER: Cressey TR 

PROVIDER: S-EPMC5508655 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates.<h4>Methods</h4>The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with <8 weeks of antiretroviral treatment before del  ...[more]

Similar Datasets

| S-EPMC7439954 | biostudies-literature
| S-EPMC7095788 | biostudies-literature
| S-EPMC6733583 | biostudies-literature
| S-EPMC7704857 | biostudies-literature
| S-EPMC9841767 | biostudies-literature
| S-EPMC5627030 | biostudies-literature
| S-EPMC6533437 | biostudies-literature
| S-EPMC3245730 | biostudies-literature
| S-EPMC7163188 | biostudies-literature
| S-EPMC8499924 | biostudies-literature